Alexion Reports Fourth Quarter and Full Year 2011 Results
- Soliris® (eculizumab) Net Product Sales Increased 45 Percent to $783
Million in 2011 -
- Continued Strong Uptake of Soliris by New PNH Patients; U.S. Launch in
aHUS Begins —
- Pipeline Progresses with Five Compounds Targeting Severe and
Ultra-Rare Disorders -
CHESHIRE, Conn.--(BUSINESS WIRE)--
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN):
Fourth Quarter 2011 Financial Highlights:
-
Q4 2011 net product sales increased 46 percent to $227.6 million,
compared to $156.0 million in Q4 2010.
-
Q4 2011 GAAP net income increased 82 percent, to $48.2 million, or
$0.25 per share, compared to Q4 2010 GAAP net income of $26.5 million,
or $0.14 per share.
-
Q4 2011 non-GAAP net income increased 65 percent to $80.5 million, or
$0.41 per share, compared to Q4 2010 non-GAAP net income of $48.6
million, or $0.26 per share.
Full-Year 2011 Financial Highlights:
-
2011 net product sales increased 45 percent to $783.4 million,
compared to $541.0 million in 2010.
-
2011 GAAP net income increased 81 percent to $175.3 million, or $0.91
per share, compared to 2010 GAAP net income of $97.0 million, or $0.52
per share.
-
2011 non-GAAP net income increased 59 percent to $266.1 million, or
$1.38 per share, compared to 2010 non-GAAP net income of $167.3
million, or $0.89 per share.
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial
results for the quarter and year ended December 31, 2011. For the three
months ended December 31, 2011, Alexion Pharmaceuticals, Inc.
("Alexion", or the "Company") reported net product sales of Soliris®
(eculizumab) of $227.6 million, compared to $156.0 million for the same
period in 2010. The year-on-year increase of 45 percent resulted
primarily from strong additions of new patients with paroxysmal
nocturnal hemoglobinuria (PNH) globally, with a small contribution from
the US launch of Soliris in atypical Hemolytic Uremic Syndrome (aHUS)
during the last months of 2011.
Soliris was approved for patients with PNH in the US (2007), European
Union (2007), Japan (2010) and other territories as the first and only
treatment indicated for this ultra-rare, debilitating and
life-threatening blood disease. In addition, in 2011, Soliris was
approved as the first and only treatment for patients with aHUS in the
US (September 2011) and European Union (November 2011). aHUS is an
ultra-rare, life-threatening, genetic disease.
Alexion's non-GAAP operating results are equal to GAAP operating results
adjusted for the impact of share-based compensation, taxes that are not
payable in cash (non-cash tax adjustment), amortization of acquired
intangible assets, and costs associated with acquisitions. The non-cash
tax adjustment represents the reduction in cash taxes attributable to
the utilization of US net operating losses. The following summary table
is provided for investors' convenience:
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands, except per share amounts)
(unaudited)
|
|
|
|
|
|
|
|
Three months ended
December
|
|
Twelve months ended
December
|
|
|
|
|
|
2011
|
|
2010
|
|
2011
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
|
$
|
227,559
|
|
|
$
|
155,975
|
|
|
$
|
783,431
|
|
|
$
|
540,957
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net income
|
|
|
|
$
|
48,170
|
|
|
$
|
26,450
|
|
|
$
|
175,315
|
|
|
$
|
97,030
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation
|
|
|
|
|
10,337
|
|
|
|
7,605
|
|
|
|
44,763
|
|
|
|
32,338
|
|
|
Acquisition-related costs
|
|
|
|
|
2,322
|
|
|
|
722
|
|
|
|
13,486
|
|
|
|
722
|
|
|
Amortization of purchased intangibles
|
|
|
|
|
104
|
|
|
|
-
|
|
|
|
382
|
|
|
|
-
|
|
|
Non-cash tax adjustment
|
|
|
|
|
19,547
|
|
|
|
13,860
|
|
|
|
32,155
|
|
|
|
37,229
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP net income
|
|
|
|
$
|
80,480
|
|
|
$
|
48,637
|
|
|
$
|
266,101
|
|
|
$
|
167,319
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in computing diluted earnings per share (GAAP)
|
|
|
|
|
193,370
|
|
|
|
188,586
|
|
|
|
191,806
|
|
|
|
186,074
|
|
|
Shares used in computing diluted earnings per share (non-GAAP)
|
|
|
|
|
194,732
|
|
|
|
190,416
|
|
|
|
193,539
|
|
|
|
188,494
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP earnings per share - diluted
|
|
|
|
$
|
0.25
|
|
|
$
|
0.14
|
|
|
$
|
0.91
|
|
|
$
|
0.52
|
|
|
Non-GAAP earnings per share - diluted
|
|
|
|
$
|
0.41
|
|
|
$
|
0.26
|
|
|
$
|
1.38
|
|
|
$
|
0.89
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter Non-GAAP Financial Results:
The Company reported non-GAAP net income of $80.5 million, or $0.41 per
share, in the fourth quarter of 2011, compared to non-GAAP net income of
$48.6 million, or $0.26 per share, in the fourth quarter of 2010.
Alexion's non-GAAP operating expenses for Q4 2011 were $111.2 million,
compared to $82.8 million for Q4 2010. Non-GAAP research and development
(R&D) expenses for Q4 2011 were $32.1 million, compared to $25.4 million
for Q4 2010. The increase in R&D expenses primarily reflected the
expansion of the Company's development programs. Non-GAAP selling,
general and administrative (SG&A) expenses for Q4 2011 were $79.1
million, compared to $57.4 million for Q4 2010. The increase in SG&A
expenses primarily reflected Alexion's growing global operations for PNH
and aHUS.
Fourth Quarter GAAP Financial Results:
Alexion reported GAAP net income of $48.2 million, or $0.25 per share in
the fourth quarter of 2011, compared to Q4 2010 GAAP net income of $26.5
million, or $0.14 per share.
On a GAAP basis, operating expenses for Q4 2011 were $123.4 million,
compared to $90.7 million for Q4 2010. GAAP R&D expenses for Q4 2011
were $34.4 million, compared to $27.2 million for Q4 2010. GAAP SG&A
expenses were $86.6 million for Q4 2011, compared to $62.8 million for
Q4 2010.
Full Year 2011 Non-GAAP Financial Results:
The Company reported non-GAAP net income of $266.1 million in 2011, or
$1.38 per share, compared to non-GAAP net income of $167.3 million, or
$0.89 per share, in 2010.
Alexion's non-GAAP operating expenses for the full year 2011 were $403.2
million, compared to $294.1 million for 2010. Non-GAAP R&D expenses for
2011 were $127.7 million, compared to $90.4 million for the prior year.
The increase in R&D expenses primarily reflected the expansion of the
Company's development programs. Non-GAAP SG&A expenses for 2011 were
$275.5 million, compared to $203.7 million in 2010. The increase in SG&A
expenses primarily reflected Alexion's growing global operations.
Full Year 2011 GAAP Financial Results:
Alexion reported GAAP net income of $175.3 million, or $0.91 per share
in 2011 compared to 2010 GAAP net income of $97.0 million, or $0.52 per
share.
Alexion's GAAP operating expenses for the full year 2011 were $459.5
million, compared to $325.9 million for the prior year. GAAP R&D
expenses for 2011 were $137.4 million, compared to $98.4 million in
2010. GAAP SG&A expenses were $308.2 million in 2011, compared to $226.8
million for the prior year.
Balance Sheet:
As of December 31, 2011, the Company had $540.9 million in cash, cash
equivalents and marketable securities compared to $361.6 million at
December 31, 2010. The year-end 2011 cash balance does not reflect the
purchase price for the Company's Enobia acquisition, which closed
February 7, 2012 and was paid for with a combination of cash on hand and
proceeds from the Company's new debt facility, and will be reflected in
Alexion's Q1 2012 results.
"Following strong performance in our major global initiatives in 2011,
we enter 2012 with the broadest commercial platform and the most robust
development pipeline in Alexion's history," said Leonard Bell, M.D.,
Chief Executive Officer of Alexion. "Throughout 2012, we will focus on
reaching more patients with PNH and serving the first patients with aHUS
in the US and Europe. At the same time, we will accelerate our
investigation of Soliris and four additional highly innovative compounds
across eight severe and ultra-rare indications."
Global Commercial Operations:
PNH
During Q4 2011, a substantial number of new patients with PNH were
started on Soliris therapy in Alexion's core territories of the US,
Western Europe and Japan. Patients with PNH in Australia and Canada, as
well as in various other nations of Europe, Asia-Pacific, and Latin
America are also receiving Soliris.
aHUS
Soliris was approved by the US Food and Drug Administration in September
and by the European Commission in November as the first
treatment for patients with aHUS. Following the US approval, Alexion
began serving patients in the US during Q4. The EU approval will enable
Alexion to begin serving patients in initial European countries in 2012.
Research and Development Progress:
Alexion currently has development programs underway with its five highly
innovative compounds: eculizumab (Soliris) and four additional novel
drugs beyond eculizumab that have the potential to become first-in-class
therapies for patients with other severe and ultra-rare disorders.
Eculizumab Programs
-
Nephrology: STEC-HUS and Acute Humoral Kidney Rejection (AHR)
Interim
data from the Company's open-label study of eculizumab in patients
with Shiga toxin E. Coli related
Hemolytic Uremic Syndrome (STEC-HUS), a severe, ultra-rare, and
life-threatening inflammatory disorder, were presented at the American
Society of Nephrology Conference in Philadelphia in November 2011.
Final data from the study is expected later in 2012.
Enrollment
has commenced in a Company-sponsored multi-national living-donor
kidney transplant trial in patients at elevated risk of AHR.
-
Neurology: NMO and MG
Programs with eculizumab are ongoing in two
severe and ultra-rare neurologic disorders, Neuromyelitis Optica (NMO)
and Myasthenia Gravis (MG). Data from the investigator initiated Phase
2 clinical trial of eculizumab in severe refractory NMO are expected
in 2012. As previously announced, data from the Company's Phase 2
study in MG were presented in the fall of 2011.
Ultra-Rare Disease Programs With Highly Innovative
Compounds Beyond Eculizumab
-
Asfotase Alfa
Asfotase alfa is an innovative, first-in-class
targeted enzyme replacement therapy in Phase 2 clinical trials for
patients with hypophosphatasia (HPP), an ultra-rare, genetic, and
life-threatening metabolic disease with no effective treatment options.
-
cPMP Replacement Therapy
Alexion is accelerating the development
of a cPMP replacement therapy for the treatment of patients with
Molybdenum Cofactor Deficiency Type A, an ultra-rare, genetic
metabolic disorder that is fatal in newborns. The Company is currently
conducting IND enabling studies.
-
TT30
Alexion is now enrolling patients in a Phase I study to
characterize the mechanism of action of TT30, a unique inhibitor of
the alternative complement pathway, and to develop initial safety data.
-
ALXN1007
A Phase I study of ALXN1007, an innovative
anti-inflammatory antibody, is underway to evaluate the safety,
tolerability, pharmacokinetics and pharmacodynamics of this compound
in healthy volunteers.
2012 Financial Guidance:
In 2012, worldwide net product sales are expected to be within a range
of $1.04 to $1.07 billion. On a non-GAAP basis, R&D expenses are
anticipated to be in the range of $220 to $230 million, and SG&A
expenses in the range of $345 to $355 million, which excludes $20 to $25
million in Enobia acquisition-related costs. The Company's share-based
compensation expense for the year is expected to be in a range of $50 to
$52 million. Cost of sales is expected to be approximately 12 percent of
net product sales. Excluding the tax impact of the integration and
structuring of the Enobia acquisition that Alexion will undertake
throughout 2012, the GAAP effective tax rate is expected to be in the
range of 32 to 34 percent. The non-GAAP effective tax rate, reported on
a cash tax liability basis, is expected to be in the range of 8 to 10
percent. Based on a forecast of approximately 197 million diluted shares
outstanding, Alexion is providing guidance of $1.60 to $1.70 for
non-GAAP earnings per share for the year.
Conference Call/Web Cast Information:
Alexion will host a conference call/webcast to discuss matters mentioned
in this release. The call is scheduled for today, February 9, at 10:00
a.m., Eastern Time. To participate in this call, dial 866-730-5770 (USA)
or 857-350-1594 (International), passcode 36208284, shortly before 10:00
a.m., Eastern Time. A replay of the call will be available for a limited
period following the call, beginning at 12:00 p.m., Eastern Time. The
replay number is 888-286-8010 (USA) or 617-801-6888 (International),
passcode 69128488. The audio webcast can be accessed at www.alexionpharma.com.
About Soliris:
Soliris is a first-in-class terminal complement inhibitor developed from
the laboratory through regulatory approval and commercialization by
Alexion. Soliris is approved in the US, European Union, Japan and other
countries as the first and only treatment for patients with paroxysmal
nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare and
life-threatening blood disorder, characterized by complement-mediated
hemolysis (destruction of red blood cells). Soliris is also approved in
the US and the European Union as the first and only treatment for
patients with atypical Hemolytic Uremic Syndrome (aHUS), a debilitating,
ultra-rare and life-threatening genetic disorder characterized by
complement-mediated thrombotic microangiopathy, or TMA (blood clots in
small vessels). Soliris is indicated to inhibit complement-mediated TMA.
The effectiveness of Soliris in aHUS is based on the effects on TMA and
renal function. Prospective clinical trials in additional patients are
ongoing to confirm the benefit of Soliris in patients with aHUS. Soliris
is not indicated for the treatment of patients with Shiga toxin E. coli
related hemolytic uremic syndrome (STEC-HUS). Alexion's breakthrough
approach in complement inhibition has received the pharmaceutical
industry's highest honors: the 2008 Prix Galien USA Award for Best
Biotechnology Product with broad implications for future biomedical
research and the 2009 Prix Galien France Award in the category of Drugs
for Rare Diseases. More information including the full prescribing
information on Soliris is available at www.soliris.net.
About Alexion:
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on
serving patients with severe and ultra-rare disorders through the
innovation, development and commercialization of life-transforming
therapeutic products. Alexion is the global leader in complement
inhibition, and has developed and markets Soliris® (eculizumab) as a
treatment for patients with PNH and aHUS, two debilitating, ultra-rare
and life-threatening disorders caused by chronic uncontrolled complement
activation. Soliris is currently approved in more than 35 countries for
the treatment of PNH, and in the United States and the European Union
for the treatment of aHUS. Alexion is evaluating other potential
indications for Soliris and is developing four other highly innovative
biotechnology product candidates. This press release and further
information about Alexion Pharmaceuticals, Inc. can be found at: www.alexionpharma.com.
[ALXN-E]
This news release contains forward-looking statements, including
statements related to guidance regarding anticipated financial results
for 2012, assessment of the Company's financial position and
commercialization efforts, medical benefits and commercial potential for
Soliris for PNH and aHUS and other potential indications, plans to
pursue reimbursement approvals in the European Union, expansion
of clinical and commercial operations to additional countries, medical
and commercial potential of Alexion's complement-inhibition technology
and other technologies, plans for clinical programs for each of our
product candidates, progress in developing commercial infrastructure,
and interest and acceptance regarding Soliris in the patient, physician
and payor communities. Forward-looking statements are subject to factors
that may cause Alexion's results and plans to differ from those
expected, including for example, decisions of regulatory authorities
regarding marketing approval or material limitations on the marketing of
Soliris for PNH and aHUS and other potential indications, delays in
arranging satisfactory manufacturing capabilities and establishing
commercial infrastructure, the possibility that results of clinical
trials are not predictive of safety and efficacy results of Soliris in
broader patient populations in the disease studied or other diseases,
the risk that recent acquisitions will not result in short-term or
long-term benefits, the possibility that current results of
commercialization are not predictive of future rates of adoption of
Soliris in PNH, aHUS or other diseases, the risk that third parties will
not agree to license any necessary intellectual property to Alexion on
reasonable terms or at all, the risk that third party payors (including
governmental agencies) will not reimburse for the use of Soliris at
acceptable rates or at all, the risk that estimates regarding the number
of patients with PNH, aHUS or other disorders is inaccurate, and a
variety of other risks set forth from time to time in Alexion's filings
with the Securities and Exchange Commission, including but not limited
to the risks discussed in Alexion's Quarterly Report on Form 10-Q for
the three and nine months ended September 30, 2011 and in our other
filings with the Securities and Exchange Commission. Alexion does not
intend to update any of these forward-looking statements to reflect
events or circumstances after the date hereof, except when a duty arises
under law.
|
|
|
ALEXION PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS
(in thousands, except per share
amounts)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
December
|
|
Twelve months ended
December
|
|
|
|
|
|
2011
|
|
|
|
2010
|
|
|
|
2011
|
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net product sales
|
|
$
|
227,559
|
|
|
$
|
155,975
|
|
|
$
|
783,431
|
|
|
$
|
540,957
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales (1)
|
|
|
28,798
|
|
|
|
20,222
|
|
|
|
93,140
|
|
|
|
64,437
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
Research and development (1)
|
|
|
34,398
|
|
|
|
27,177
|
|
|
|
137,421
|
|
|
|
98,394
|
|
|
|
Selling, general and administrative (1)
|
|
|
86,567
|
|
|
|
62,825
|
|
|
|
308,176
|
|
|
|
226,766
|
|
|
|
Acquisition-related costs (2)
|
|
|
2,322
|
|
|
|
722
|
|
|
|
13,486
|
|
|
|
722
|
|
|
|
Amortization of purchased intangibles
|
|
|
104
|
|
|
|
-
|
|
|
|
382
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
123,391
|
|
|
|
90,724
|
|
|
|
459,465
|
|
|
|
325,882
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
75,370
|
|
|
|
45,029
|
|
|
|
230,826
|
|
|
|
150,638
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other expense
|
|
|
(1,292
|
)
|
|
|
(782
|
)
|
|
|
(1,158
|
)
|
|
|
(1,627
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes
|
|
|
74,078
|
|
|
|
44,247
|
|
|
|
229,668
|
|
|
|
149,011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax provision (3)
|
|
|
25,908
|
|
|
|
17,797
|
|
|
|
54,353
|
|
|
|
51,981
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
48,170
|
|
|
$
|
26,450
|
|
|
$
|
175,315
|
|
|
$
|
97,030
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per common share
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
0.26
|
|
|
$
|
0.15
|
|
|
$
|
0.96
|
|
|
$
|
0.54
|
|
|
|
Diluted
|
|
$
|
0.25
|
|
|
$
|
0.14
|
|
|
$
|
0.91
|
|
|
$
|
0.52
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used in computing earnings per common share
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
184,452
|
|
|
|
180,136
|
|
|
|
183,220
|
|
|
|
178,542
|
|
|
|
Diluted
|
|
|
193,370
|
|
|
|
188,586
|
|
|
|
191,806
|
|
|
|
186,074
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
The following table summarizes the share-based compensation expense
included in the respective captions of the condensed consolidated
statements of operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
December
|
|
Twelve months ended
December
|
|
|
|
|
|
2011
|
|
|
|
2010
|
|
|
|
2011
|
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
$
|
613
|
|
|
$
|
411
|
|
|
$
|
2,375
|
|
|
$
|
1,266
|
|
|
|
Research and development
|
|
|
2,270
|
|
|
|
1,739
|
|
|
|
9,759
|
|
|
|
7,878
|
|
|
|
Selling, general and administrative
|
|
|
7,454
|
|
|
|
5,455
|
|
|
|
32,629
|
|
|
|
23,194
|
|
|
|
|
|
$
|
10,337
|
|
|
$
|
7,605
|
|
|
$
|
44,763
|
|
|
$
|
32,338
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2)
|
The following table summarizes the acquisition-related costs
included in the condensed consolidated statements of operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
December
|
|
Twelve months ended
December
|
|
|
|
|
|
2011
|
|
|
|
2010
|
|
|
|
2011
|
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Transaction and separation costs
|
|
$
|
2,039
|
|
|
$
|
722
|
|
|
$
|
12,086
|
|
|
$
|
722
|
|
|
|
Adjustments to fair value of contingent consideration
|
|
|
283
|
|
|
|
-
|
|
|
|
1,400
|
|
|
|
-
|
|
|
|
|
|
$
|
2,322
|
|
|
$
|
722
|
|
|
$
|
13,486
|
|
|
$
|
722
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3)
|
The following table summarizes the non-cash tax adjustment, which
represents the reduction in cash taxes attributable to the
utilization of US net operating losses (NOL's):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
December
|
|
Twelve months ended
December
|
|
|
|
|
|
2011
|
|
|
|
2010
|
|
|
|
2011
|
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash tax adjustment
|
|
$
|
19,547
|
|
|
$
|
13,860
|
|
|
$
|
32,155
|
|
|
$
|
37,229
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ALEXION PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED
BALANCE SHEETS
(in thousands)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
2011
|
|
December 31,
2010
|
|
Cash, cash equivalents and marketable securities
|
|
$
|
540,865
|
|
|
$
|
361,605
|
|
|
Trade accounts receivable, net
|
|
|
244,288
|
|
|
|
168,732
|
|
|
Inventories
|
|
|
81,386
|
|
|
|
62,165
|
|
|
Deferred tax assets, current
|
|
|
19,132
|
|
|
|
19,643
|
|
|
Other current assets
|
|
|
55,599
|
|
|
|
34,411
|
|
|
Property, plant and equipment, net
|
|
|
165,852
|
|
|
|
162,240
|
|
|
Deferred tax assets, noncurrent
|
|
|
103,868
|
|
|
|
154,569
|
|
|
Intangibles assets, net
|
|
|
91,604
|
|
|
|
24,146
|
|
|
Goodwill
|
|
|
79,639
|
|
|
|
19,954
|
|
|
Other noncurrent assets
|
|
|
12,518
|
|
|
|
4,572
|
|
|
Total assets
|
|
$
|
1,394,751
|
|
|
$
|
1,012,037
|
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses
|
|
$
|
202,093
|
|
|
$
|
123,056
|
|
|
Other current liabilities
|
|
|
28,132
|
|
|
|
15,459
|
|
|
Long-term debt
|
|
|
-
|
|
|
|
3,718
|
|
|
Contingent consideration
|
|
|
18,120
|
|
|
|
-
|
|
|
Other noncurrent liabilities
|
|
|
11,914
|
|
|
|
10,068
|
|
|
Total liabilities
|
|
|
260,259
|
|
|
|
152,301
|
|
|
|
|
|
|
|
|
Total stockholders' equity
|
|
|
1,134,492
|
|
|
|
859,736
|
|
|
Total liabilities and stockholders' equity
|
|
$
|
1,394,751
|
|
|
$
|
1,012,037
|
|
Alexion Pharmaceuticals, Inc.
Irving Adler, 203-271-8210
Sr.
Director, Corporate Communications
or
Kim Diamond (Media),
203-439-9600
Director, Corporate Communications
or
Rx
Communications (Investors)
Rhonda Chiger, 917-322-2569
Source: Alexion Pharmaceuticals, Inc.
News Provided by Acquire Media